Treated with a stable dose of one of the following for at least 3 months prior to screening: * >=1000 mg/day immediate-release metformin; or metformin >=1000 mg/day and sulfonylurea; or sulfonylurea/metformin combination therapy. 
HbA1c between 7.1% and 11.0%, inclusive. 
Body Mass Index (BMI) >21 kg/m^2 and <35 kg/m^2. 

NCT00324363_inc_T1
Qualifier
stable dose
NCT00324363_inc_T2
Temporal
at least 3 months prior to screening
NCT00324363_inc_T3
Drug
immediate-release metformin
NCT00324363_inc_T4
Value
>=1000 mg/day
NCT00324363_inc_T5
Drug
metformin
NCT00324363_inc_T6
Value
>=1000 mg/day
NCT00324363_inc_T7
Drug
sulfonylurea
NCT00324363_inc_T8
Drug
sulfonylurea
NCT00324363_inc_T9
Drug
metformin
NCT00324363_inc_T10
Procedure
combination therapy
NCT00324363_inc_T11
Scope
metformin >=1000 mg/day and sulfonylurea
NCT00324363_inc_T12
Scope
>=1000 mg/day immediate-release metformin; or metformin >=1000 mg/day and sulfonylurea; or sulfonylurea/metformin combination therapy
NCT00324363_inc_T13
Measurement
HbA1c
NCT00324363_inc_T14
Value
between 7.1% and 11.0%, inclusive
NCT00324363_inc_T15
Measurement
Body Mass Index (BMI)
NCT00324363_inc_T16
Value
>21 kg/m^2 and <35 kg/m^2
NCT00324363_inc_T17
Reference_point
screening
NCT00324363_inc_T18
Multiplier
one of the following